Aevi Genomic Medicine Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 14

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $23.5M

Aevi Genomic Medicine General Information

Description

Medgenics is a clinical-stage biopharmaceutical company involved mainly in genomic medicine. Genomic medicine involves the usage of individual's genomic information to decide upon clinical care. This medical discipline is used in the fields of oncology, pharmacology, rare and undiagnosed diseases, and infectious diseases. Medgenics' partner is the Center for Applied Genomics at the Children's Hospital of Philadelphia, with which it works to develop drugs by implementing genomics medicine.

Contact Information

Formerly Known As
Biogenics, MedGenics
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 435 Devon Park Drive
  • Suite 715
  • Wayne, PA 19087
  • United States
+1 (610)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 435 Devon Park Drive
  • Suite 715
  • Wayne, PA 19087
  • United States
+1 (610)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Aevi Genomic Medicine Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Merger/Acquisition 03-Feb-2020 $23.5M Completed Generating Revenue
11. PIPE 17-Oct-2017 Completed Generating Revenue
10. 2PO 24-Jun-2016 Completed Generating Revenue
9. PIPE 19-Jun-2012 Completed Generating Revenue
8. Debt - General 04-Nov-2010 Completed Generating Revenue
7. PIPE 26-May-2010 Completed Generating Revenue
6. Debt - General 23-Jun-2009 Completed Generating Revenue
5. IPO 04-Dec-2007 Completed Generating Revenue
4. Angel (individual) 19-Apr-2006 $27K $19.6M Completed Startup
3. Early Stage VC (Series B) 25-Apr-2003 $12.3M $19.5M Completed Startup
To view Aevi Genomic Medicine’s complete valuation and funding history, request access »

Aevi Genomic Medicine Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B1
Series B
Series A1 4,224,339 $0.000100 $0.14 $1.71 $1.71 1x $1.71
Series A 4,224,339 $0.000100 $0.14 $1.71 $1.71 1x $1.71 26.99%
To view Aevi Genomic Medicine’s complete cap table history, request access »

Aevi Genomic Medicine Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Medgenics is a clinical-stage biopharmaceutical company involved mainly in genomic medicine. Genomic medicine involves t
Drug Discovery
Wayne, PA
14 As of 2018

Wayne, PA
 

Philadelphia, PA
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Aevi Genomic Medicine Competitors (33)

One of Aevi Genomic Medicine’s 33 competitors is Palvella Therapeutics, a Formerly VC-backed company based in Wayne, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Palvella Therapeutics Formerly VC-backed Wayne, PA
Limelight Bio Formerly VC-backed Philadelphia, PA
TCG Lifesciences Corporation Kolkata, India
Personalis Formerly VC-backed Fremont, CA
OpGen Formerly VC-backed Rockville, MD
You’re viewing 5 of 33 competitors. Get the full list »

Aevi Genomic Medicine Patents

Aevi Genomic Medicine Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20190030128-A1 Compositions and methods for treatment of central nervous system diseases Inactive 11-Jan-2016
EP-3402531-A1 Compositions and methods for treatment of central nervous system diseases Inactive 11-Jan-2016
EP-3402531-A4 Compositions and methods for treatment of central nervous system diseases Inactive 11-Jan-2016
US-20160122713-A1 Genetically-modified micro-organ secreting a therapeutic peptide and methods of use thereof Inactive 14-Oct-2014
US-20150118187-A1 Micro-organs providing sustained delivery of a therapeutic polypeptide and methods of use thereof Inactive 24-Oct-2013 A61K38/1816
To view Aevi Genomic Medicine’s complete patent history, request access »

Aevi Genomic Medicine Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Aevi Genomic Medicine Former Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alta Partners Venture Capital Minority
Angel (individual) Minority
CIBC Capital Markets Investment Bank Minority
Chicago Private Investments Other Minority
Children's Hospital of Philadelphia Impact Investing Minority
You’re viewing 5 of 11 investors. Get the full list »

Aevi Genomic Medicine Acquisitions (1)

Aevi Genomic Medicine’s most recent deal was a Merger/Acquisition with neuroFix Therapeutics for . The deal was made on 09-Sep-2015.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
neuroFix Therapeutics 09-Sep-2015 Merger/Acquisition Drug Discovery
To view Aevi Genomic Medicine’s complete acquisitions history, request access »

Aevi Genomic Medicine ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Aevi Genomic Medicine’s complete esg history, request access »

Aevi Genomic Medicine FAQs

  • When was Aevi Genomic Medicine founded?

    Aevi Genomic Medicine was founded in 2000.

  • Where is Aevi Genomic Medicine headquartered?

    Aevi Genomic Medicine is headquartered in Wayne, PA.

  • What is the size of Aevi Genomic Medicine?

    Aevi Genomic Medicine has 14 total employees.

  • What industry is Aevi Genomic Medicine in?

    Aevi Genomic Medicine’s primary industry is Drug Discovery.

  • Is Aevi Genomic Medicine a private or public company?

    Aevi Genomic Medicine is a Private company.

  • What is the current valuation of Aevi Genomic Medicine?

    The current valuation of Aevi Genomic Medicine is .

  • What is Aevi Genomic Medicine’s current revenue?

    The current revenue for Aevi Genomic Medicine is .

  • How much funding has Aevi Genomic Medicine raised over time?

    Aevi Genomic Medicine has raised $89.5M.

  • Who are Aevi Genomic Medicine’s investors?

    Alta Partners, , CIBC Capital Markets, Chicago Private Investments, and Children's Hospital of Philadelphia are 5 of 11 investors who have invested in Aevi Genomic Medicine.

  • Who are Aevi Genomic Medicine’s competitors?

    Palvella Therapeutics, Limelight Bio, TCG Lifesciences, Personalis, and OpGen are some of the 33 competitors of Aevi Genomic Medicine.

  • When was Aevi Genomic Medicine acquired?

    Aevi Genomic Medicine was acquired on 03-Feb-2020.

  • Who acquired Aevi Genomic Medicine?

    Aevi Genomic Medicine was acquired by Avalo Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »